Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual...

redorbit.com     May 16, 2008            

Posted on: Friday, 16 May 2008, 09:01 CDT CALGARY, May 16 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract covering interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung is... [read full story]                    

Full Coverage

Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in...

redorbit.com     May 14, 2008          

Posted on: Wednesday, 14 May 2008, 03:00 CDT CALGARY, May 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its...                    

comments

Trial Investigates REOLYSIN In Combination With Paclitaxel, Carboplatin

emaxhealth.com     May 15, 2008          

Oncolytics Biotech has received a letter of approval from MHRA for its CTA to begin a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.                    

comments